CN113817051B - 一种抗SARS-CoV-2的单克隆抗体1B6 - Google Patents
一种抗SARS-CoV-2的单克隆抗体1B6 Download PDFInfo
- Publication number
- CN113817051B CN113817051B CN202010566595.2A CN202010566595A CN113817051B CN 113817051 B CN113817051 B CN 113817051B CN 202010566595 A CN202010566595 A CN 202010566595A CN 113817051 B CN113817051 B CN 113817051B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- seq
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 14
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 101800000904 Spike protein S1 Proteins 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 description 19
- 230000027455 binding Effects 0.000 description 13
- 230000000903 blocking effect Effects 0.000 description 13
- 238000001514 detection method Methods 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 description 4
- 230000010530 Virus Neutralization Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YSUVMPICYVWRBX-VEVYYDQMSA-N Arg-Asp-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YSUVMPICYVWRBX-VEVYYDQMSA-N 0.000 description 2
- WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 2
- NTWOPSIUJBMNRI-KKUMJFAQSA-N Asn-Lys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTWOPSIUJBMNRI-KKUMJFAQSA-N 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 2
- ZSWGJYOZWBHROQ-RWRJDSDZSA-N Glu-Ile-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSWGJYOZWBHROQ-RWRJDSDZSA-N 0.000 description 2
- MUARUIBTKQJKFY-WHFBIAKZSA-N Ser-Gly-Asp Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MUARUIBTKQJKFY-WHFBIAKZSA-N 0.000 description 2
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 2
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 2
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 2
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 2
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- PQWTZSNVWSOFFK-FXQIFTODSA-N Arg-Asp-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N PQWTZSNVWSOFFK-FXQIFTODSA-N 0.000 description 1
- OTCJMMRQBVDQRK-DCAQKATOSA-N Arg-Asp-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O OTCJMMRQBVDQRK-DCAQKATOSA-N 0.000 description 1
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 description 1
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 1
- WLVLIYYBPPONRJ-GCJQMDKQSA-N Asn-Thr-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O WLVLIYYBPPONRJ-GCJQMDKQSA-N 0.000 description 1
- YQPSDMUGFKJZHR-QRTARXTBSA-N Asn-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)N YQPSDMUGFKJZHR-QRTARXTBSA-N 0.000 description 1
- NJPLPRFQLBZAMH-IHRRRGAJSA-N Asn-Tyr-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(O)=O NJPLPRFQLBZAMH-IHRRRGAJSA-N 0.000 description 1
- VAWNQIGQPUOPQW-ACZMJKKPSA-N Asp-Glu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VAWNQIGQPUOPQW-ACZMJKKPSA-N 0.000 description 1
- KFAFUJMGHVVYRC-DCAQKATOSA-N Asp-Leu-Met Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O KFAFUJMGHVVYRC-DCAQKATOSA-N 0.000 description 1
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- ALMIMUZAWTUNIO-BZSNNMDCSA-N Asp-Tyr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ALMIMUZAWTUNIO-BZSNNMDCSA-N 0.000 description 1
- GYNUXDMCDILYIQ-QRTARXTBSA-N Asp-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N GYNUXDMCDILYIQ-QRTARXTBSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVFQOPGFOQVZTE-ACZMJKKPSA-N Cys-Gln-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O BVFQOPGFOQVZTE-ACZMJKKPSA-N 0.000 description 1
- OVQXQLWWJSNYFV-XEGUGMAKSA-N Gln-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(N)=O)C)C(O)=O)=CNC2=C1 OVQXQLWWJSNYFV-XEGUGMAKSA-N 0.000 description 1
- MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 1
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 1
- YPFFHGRJCUBXPX-NHCYSSNCSA-N Gln-Pro-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O)C(O)=O YPFFHGRJCUBXPX-NHCYSSNCSA-N 0.000 description 1
- LVCHEMOPBORRLB-DCAQKATOSA-N Glu-Gln-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O LVCHEMOPBORRLB-DCAQKATOSA-N 0.000 description 1
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
- HQTDNEZTGZUWSY-XVKPBYJWSA-N Glu-Val-Gly Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)NCC(O)=O HQTDNEZTGZUWSY-XVKPBYJWSA-N 0.000 description 1
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- QPCVIQJVRGXUSA-LURJTMIESA-N Gly-Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QPCVIQJVRGXUSA-LURJTMIESA-N 0.000 description 1
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- OJNZVYSGVYLQIN-BQBZGAKWSA-N Gly-Met-Asp Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O OJNZVYSGVYLQIN-BQBZGAKWSA-N 0.000 description 1
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 1
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 1
- ZLFNNVATRMCAKN-ZKWXMUAHSA-N Ile-Ser-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZLFNNVATRMCAKN-ZKWXMUAHSA-N 0.000 description 1
- RKQAYOWLSFLJEE-SVSWQMSJSA-N Ile-Thr-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)O)N RKQAYOWLSFLJEE-SVSWQMSJSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- OOSPRDCGTLQLBP-NHCYSSNCSA-N Met-Glu-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OOSPRDCGTLQLBP-NHCYSSNCSA-N 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 1
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 1
- PULPZRAHVFBVTO-DCAQKATOSA-N Pro-Glu-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PULPZRAHVFBVTO-DCAQKATOSA-N 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- SQBLRDDJTUJDMV-ACZMJKKPSA-N Ser-Glu-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQBLRDDJTUJDMV-ACZMJKKPSA-N 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- CKDXFSPMIDSMGV-GUBZILKMSA-N Ser-Pro-Val Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O CKDXFSPMIDSMGV-GUBZILKMSA-N 0.000 description 1
- RTXKJFWHEBTABY-IHPCNDPISA-N Ser-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CO)N RTXKJFWHEBTABY-IHPCNDPISA-N 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- OYTNZCBFDXGQGE-XQXXSGGOSA-N Thr-Gln-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O OYTNZCBFDXGQGE-XQXXSGGOSA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 1
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- LTLBNCDNXQCOLB-UBHSHLNASA-N Trp-Asp-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 LTLBNCDNXQCOLB-UBHSHLNASA-N 0.000 description 1
- BURPTJBFWIOHEY-UWJYBYFXSA-N Tyr-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BURPTJBFWIOHEY-UWJYBYFXSA-N 0.000 description 1
- KYPMKDGKAYQCHO-RYUDHWBXSA-N Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KYPMKDGKAYQCHO-RYUDHWBXSA-N 0.000 description 1
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- BZWUSZGQOILYEU-STECZYCISA-N Val-Ile-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BZWUSZGQOILYEU-STECZYCISA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- WBPFYNYTYASCQP-CYDGBPFRSA-N Val-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N WBPFYNYTYASCQP-CYDGBPFRSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及一种抗SARS‑CoV‑2的单克隆抗体1B6,该抗体的六个CDR区为:(1)重链CDR1(VHCDR1)包含如SEQ ID NO.1所示的氨基酸序列;(2)重链CDR2(VHCDR2)包含如SEQ ID NO.2所示的氨基酸序列;(3)重链CDR3(VHCDR3)包含如SEQ ID NO.3所示的氨基酸序列;(4)轻链CDR1(VLCDR1)包含如SEQ ID NO.4所示的氨基酸序列;(5)轻链CDR2(VLCDR2)包含如SEQ ID NO.5所示的氨基酸序列;(6)轻链CDR3(VLCDR3)包含如SEQ ID NO.6所示的氨基酸序列。
Description
技术领域
本发明属于生物医药技术领域,具体的,涉及一种抗SARS-CoV-2的单克隆抗体1B6。
背景技术
含有高浓度的抗SARS-CoV-2抗体的康复期血浆已在治疗中显示出积极的效果,说明抗SARS-CoV-2特异性抗体能有效阻断病毒与细胞的结合。另外,在SARS、MERS等烈性传染病爆发期间研发了一系列的具有中和活性的单克隆抗体,已被证明在疾病的预防和治疗中具有安全性和有效性。这些都提示在应对SARS-CoV-2病毒时,可考虑制备抗SARS-CoV-2单克隆抗体,尤其是全人源单克隆抗体,该种抗体不仅能通过阻断SARS-CoV-2与受体细胞的结合从而避免病毒的侵入,达到保护的作用,而且相对人源化或人鼠嵌合抗体具有副作用更小的优点,将为COVID-19的特异性预防和治疗提供新的手段。
发明内容
本发明首先涉及针对SARS-CoV-2病毒的单克隆抗体1B6,其特征在于,该抗体的六个CDR区为:
(1)重链CDR1(VHCDR1)包含如SEQ ID NO.1所示的氨基酸序列:EITVSSNYMN;
(2)重链CDR2(VHCDR2)包含如SEQ ID NO.2所示的氨基酸序列:VIYSGGTTYYADSVKG;
(3)重链CDR3(VHCDR3)包含如SEQ ID NO.3所示的氨基酸序列:DLMEVGGMDV;
(4)轻链CDR1(VLCDR1)包含如SEQ ID NO.4所示的氨基酸序列:SGDNLGNKYVS;
(5)轻链CDR2(VLCDR2)包含如SEQ ID NO.5所示的氨基酸序列:RDTQRPS;
(6)轻链CDR3(VLCDR3)包含如SEQ ID NO.6所示的氨基酸序列:QAWDSTTAV。
进一步的,
所述的单克隆抗体1B6的重链可变区全长包含如SEQ ID NO.7所示的氨基酸序列:EVQLLESGGGLVQPGGSLRLSCAASEITVSSNYMNWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDNSENTLYLQMNSL RAEDTAVYYCARDLMEVGGMDVWGQGTTVTVSS;
所述的单克隆抗体1B6的轻链可变区全长包含如SEQ ID NO.8所示的氨基酸序列:QPVLTQPPSVSVSPGQTASITCSGDNLGNKYVSWYEQKPGQSPVVVIYRDTQRPSGIPERYSGSNSGNTATLTISGTQALDEADYYC QAWDSTTAVFGGGTKLTVL。
进一步的,所述的单克隆抗体1B6为人IgG型抗体。
进一步的,所述的单克隆抗体1B6结合的抗原为SARS-CoV-2病毒的刺突蛋白S1,具体的,所述的单克隆抗体1B6结合的抗原结构区域为SARS-CoV-2病毒的刺突蛋白S1中的RBD结构域。
最优选的,所述的单克隆抗体1B6的轻链可变区和重链可变区分别是SEQ ID NO.8和SEQ ID NO.7所示的氨基酸序列。
本发明还涉及编码所述单克隆抗体1B6的核酸片段。
本发明还涉及一种抗体,所述的抗体的轻链为:
(1)SEQ ID NO.8所示的氨基酸序列经替换、缺失或添加一个或几个氨基酸后,形成的具有同等功能的序列;
或(2)与SEQ ID NO.8所示的氨基酸序列具有95%以上同源性的氨基酸序列;
所述的抗体的重链为:
(1)SEQ ID NO.7所示的氨基酸序列经替换、缺失或添加一个或几个氨基酸后,形成的具有同等功能的序列;
或(2)与SEQ ID NO.7所示的氨基酸序列具有95%以上同源性的氨基酸序列。
本发明还包括所述的单克隆抗体1B6在制备检测SARS-CoV-2病毒的试剂中的应用。
本发明还包括所述的单克隆抗体1B6在制备抑制SARS-CoV-2病毒的试剂中的应用。
本发明还包括单克隆抗体1B6在制备药物中的应用,所述的药物为预防和/或治疗因SARS-CoV-2病毒感染导致的疾病的药物。
本发明的有益效果:由于目前针对SARS-CoV-2病毒引起的疾病仍无上市的疫苗和特异药物,虽然康复期血浆治疗已被证明是一种有希望的治疗方法,但是由于大规模制备受限,且该方法主要针对重症和危重症患者,而单克隆抗体则具有纯度高,靶向性强、副作用小、可大量制备等优点。本发明所涉及的1B6抗体的实验结果表明,该单克隆抗体1B6中和活性和阻断活性均较高。因此,本发明获得的人源单克隆抗体 1B6为COVID-19的特异性预防和治疗提供了新的候选药物。
附图说明
图1、单克隆抗体1B6的SDS-PAGE电泳检测结果:泳道1为非还原SDS-PAGE电泳,泳道2为还原 SDS-PAGE电泳。
图2、单克隆抗体1B6的SEC-HPLC检测结果。
图3、单克隆抗体1B6结合活性检测结果。A为针对SARS-CoV-2刺突蛋白S1的结合活性;B为针对 SARS-CoV-2刺突蛋白S1的RBD结构域的结合活性。
图4、单克隆抗体1B6阻断活性检测结果。A为针对SARS-CoV-2刺突蛋白S1的阻断活性;B为针对 SARS-CoV-2刺突蛋白S1的RBD结构域的阻断活性。
图5、单克隆抗体1B6亲和力检测结果。
图6、单克隆抗体1B6的活病毒中和实验检测结果。
具体实施方式
若未特别说明,以下实施例中所用的技术手段均为本领域技术人员所熟知的常规手段,所有试剂耗材均为市售商品。
实施例1、单克隆抗体1B6表达载体的构建、表达与纯化
将含1B6抗体重链和轻链可变区的编码基因片段分别整合入含人IgG1抗体重轻链恒定区序列的 pcDNA3.4表达载体中,得到能分别表达目标抗体重链和轻链的重组表达载体。
细胞的转染、抗体表达和纯化
1、转染:采用Gibco公司转染试剂盒并按照说明书进行转染操作,步骤简述为:
将两种重组表达载体总DNA与转染试剂混合以形成DNA ExpiFectamineTM 293复合物;
随后加入含40mL、2.94x106个/mL的Expi293细胞培养物中;
最后置于37℃,125rpm,8%CO2培养。
2、纯化:
培养5天后,4000rpm,25℃离心10分钟收集上清,随后用MabSelect Sure亲和层析柱进行纯化。纯化步骤简述为:
用pH7.0的0.1M Tris缓冲液平衡;
上样后,用pH7.0的0.1M Tris缓冲液淋洗;
随后用pH8.0的1.0M Tris缓冲液进行洗脱。
收集洗脱液进一步于PBS缓冲液中透析。取纯化后的抗体进行SDS-PAGE和HPLC-SEC检测分析。
3、结果分析:SDS-PAGE结果见图1,显示在非还原条件下,人源SARS-CoV-2抗体呈现分子量约为150kDa 的条带;在还原条件下呈现分子量约为50kDa和25kDa的两条带,分别对应抗体的重链和轻链。SEC-HPLC结果见图2,显示纯化后的单克隆抗体纯度达到98%以上。纯化后的单克隆抗体经肽图分析后得到的氨基酸序列与预期的氨基酸序列一致。具体的,轻链可变区和重链可变区的序列分别与SEQ ID NO.8、SEQ ID NO.7相同。
实施例2、抗体的功能分析
1、人源抗SARS-CoV-2抗体1B6与抗原的结合活性检测
采用ELISA法测定抗体与SARS-CoV-2病毒的刺突蛋白S1和其RBD结构域结合能力。步骤简述为:
(1)以SARS-CoV-2刺突S1-His重组蛋白(Sino公司,货号:40591-V08H)或RBD结构域重组蛋白(Sino 公司,货号40592-V05H)为包被抗原,用重碳酸盐缓冲液将1.0μg/mL抗原包被于酶标板,4℃过夜;
(2)用酪蛋白缓冲液于37℃封闭1h;加入系列稀释后的待检抗体,37℃1h;
(3)加入1:10000稀释后的羊抗人IgG-HRP(Bethyl公司,货号:A80-304P),37℃1h;
(4)用显色液显色后,2M HCl终止反应;酶标仪检测吸光度A450和A540值。
结果:
1B6抗体与抗原结合活性检测结果见图3,可知单克隆抗体1B6针对S1蛋白的结合活性(图3A)为 EC50=0.047nM;针对RBD结构域的结合活性(图3B)为EC50=0.043nM。
2、人源抗SARS-CoV-2抗体1B6的阻断活性检测
采用ELISA检测法检测抗体阻断ACE2重组蛋白(带His标签)结合SARS-CoV-2(2019-nCoV)病毒的刺突蛋白S1和RBD结构域的能力。步骤简述为:
(1)以SARS-CoV-2刺突S1亚基蛋白(Sino公司,货号:40591-V02H)或RBD结构域的重组蛋白(Sino 公司,货号40592-V05H)为包被抗原,用重碳酸盐缓冲液将1.0μg/mL抗原包被于酶标板,4℃过夜;
(2)用酪蛋白缓冲液于37℃封闭1h;加入系列稀释后的待检抗体和浓度为0.5μg/mL或0.02μg/mL的 ACE重组蛋白进行共孵育,37℃1h;
(3)加入1:3000稀释后的生物素标记的小鼠抗His标签抗体(GenScript公司,货号:A00613),37℃ 1h;
(4)加入1:20000稀释的链霉亲和素-HRP(Thermofisher公司,货号:SNN1004),37℃1h;用显色液显色后,2M HCl终止反应;酶标仪检测吸光度A450和A540值。
结果:
1B6抗体阻断活性检测结果见图4,可知单克隆抗体1B6针对ACE2与S1结合的阻断活性(图4A)为 IC50=3.884nM,最大阻断率为94.04%;针对ACE2与RBD结合的阻断活性为(图4B)为IC50=3.25nM,最大阻断率为99.08%。
3、人源抗SARS-CoV-2抗体1B6的亲和力检测
利用GE公司的Biacore 8K仪器进行表面等离子共振实验,检测抗体亲和力。
单克隆抗体1B6亲和力检测结果见图5,可知1B6结合常数ka值为1.21E+05 1/Ms,解离常数kd值为 1.37E-03 1/s,亲和力常数KD值为1.13E-08M。
4、人源抗SARS-CoV-2抗体活病毒中和试验
病毒蚀斑减少中和试验采用SARS-CoV-2病毒BetaCoV/IVDC-HB-envF13/2020株进行。步骤简述为:将定量的SARS-CoV-2病毒和系列倍比稀释的单克隆抗体混合后孵育,然后加入到预先准备好的含Vero细胞的检测平板中,培养后观察记录病毒蚀斑数,并计算病毒中和活性(以IC50表示)。
结果:
抗体1B6的活病毒中和实验检测结果见图6,可知该单克隆抗体能较好的中和SARS-CoV-2病毒 (IC50<48.8ng/mL)。
最后需要说明的是,以上实施例仅用作帮助本领域技术人员理解本发明的实质,不用于限定本发明的保护范围。
SEQUENCE LISTING
<110> 武汉生物制品研究所有限责任公司
<120> 一种抗SARS-CoV-2的单克隆抗体1B6
<210> 1
<211> 10
<212> PRT
<213> 人工序列
<400> 1
Glu Ile Thr Val Ser Ser Asn Tyr Met Asn
1 5 10
<210> 2
<211> 16
<212> PRT
<213> 人工序列
<400> 2
Val Ile Tyr Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 3
<211> 10
<212> PRT
<213> 人工序列
<400> 3
Asp Leu Met Glu Val Gly Gly Met Asp Val
1 5 10
<210> 4
<211> 11
<212> PRT
<213> 人工序列
<400> 4
Ser Gly Asp Asn Leu Gly Asn Lys Tyr Val Ser
1 5 10
<210> 5
<211> 7
<212> PRT
<213> 人工序列
<400> 5
Arg Asp Thr Gln Arg Pro Ser
1 5
<210> 6
<211> 9
<212> PRT
<213> 人工序列
<400> 6
Gln Ala Trp Asp Ser Thr Thr Ala Val
1 5
<210> 7
<211> 118
<212> PRT
<213> 人工序列
<400> 7
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Tyr Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Leu Met Glu Val Gly Gly Met Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 8
<211> 106
<212> PRT
<213> 人工序列
<400> 8
Gln Pro Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15
Thr Ala Ser Ile Thr Cys Ser Gly Asp Asn Leu Gly Asn Lys Tyr Val
20 25 30
Ser Trp Tyr Glu Gln Lys Pro Gly Gln Ser Pro Val Val Val Ile Tyr
35 40 45
Arg Asp Thr Gln Arg Pro Ser Gly Ile Pro Glu Arg Tyr Ser Gly Ser
50 55 60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Leu
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Thr Thr Ala Val
85 90 95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
Claims (8)
1.一种抗SARS-CoV-2病毒的单克隆抗体1B6,其特征在于,该抗体的六个CDR区为:
(1)重链CDR1(VHCDR1)如SEQ ID NO.1所示的氨基酸序列:EITVSSNYMN;
(2)重链CDR2(VHCDR2)如SEQ ID NO.2所示的氨基酸序列:VIYSGGTTYYADSVKG;
(3)重链CDR3(VHCDR3)如SEQ ID NO.3所示的氨基酸序列:DLMEVGGMDV;
(4)轻链CDR1(VLCDR1)如SEQ ID NO.4所示的氨基酸序列:SGDNLGNKYVS;
(5)轻链CDR2(VLCDR2)如SEQ ID NO.5所示的氨基酸序列:RDTQRPS;
(6)轻链CDR3(VLCDR3)如SEQ ID NO.6所示的氨基酸序列:QAWDSTTAV。
2.根据权利要求1所述的抗体,其特征在于,
所述的单克隆抗体1B6的重链可变区全长如SEQ ID NO.7所示的氨基酸序列:
所述的单克隆抗体1B6的轻链可变区全长如SEQ ID NO.8所示的氨基酸序列。
3.根据权利要求1或2所述的抗体,其特征在于,所述的单克隆抗体1B6为人IgG型抗体。
4.根据权利要求1或2所述的抗体,其特征在于,所述的单克隆抗体1B6结合的抗原结构区域为SARS-CoV-2病毒的刺突蛋白S1中的RBD结构域。
5.编码权利要求1-4任一所述的抗体的核酸片段。
6.权利要求1-4任一所述的单克隆抗体1B6在制备检测SARS-CoV-2病毒的试剂中的应用。
7.权利要求1-4任一所述的单克隆抗体1B6在制备抑制SARS-CoV-2病毒的试剂中的应用。
8.权利要求1-4任一所述的单克隆抗体1B6在制备药物中的应用,所述的药物为预防和/或治疗因SARS-CoV-2病毒感染导致的疾病的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010566595.2A CN113817051B (zh) | 2020-06-19 | 2020-06-19 | 一种抗SARS-CoV-2的单克隆抗体1B6 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010566595.2A CN113817051B (zh) | 2020-06-19 | 2020-06-19 | 一种抗SARS-CoV-2的单克隆抗体1B6 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113817051A CN113817051A (zh) | 2021-12-21 |
CN113817051B true CN113817051B (zh) | 2023-08-29 |
Family
ID=78911633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010566595.2A Active CN113817051B (zh) | 2020-06-19 | 2020-06-19 | 一种抗SARS-CoV-2的单克隆抗体1B6 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113817051B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114835805B (zh) * | 2022-06-10 | 2023-06-06 | 郑州大学 | 抗SARS-CoV-2 spike蛋白的单克隆抗体及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111153991A (zh) * | 2020-02-26 | 2020-05-15 | 北京博奥森生物技术有限公司 | 一种人SARS-CoV-2单克隆抗体及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10688182B2 (en) * | 2018-03-29 | 2020-06-23 | Cho Pharma Usa, Inc. | Monoclonal antibodies that bind to SSEA4 and uses thereof |
-
2020
- 2020-06-19 CN CN202010566595.2A patent/CN113817051B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111153991A (zh) * | 2020-02-26 | 2020-05-15 | 北京博奥森生物技术有限公司 | 一种人SARS-CoV-2单克隆抗体及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
侯江厚 ; 张灵霞 ; 黄国红 ; 詹晓燕 ; 杨奕梅 ; .新型冠状病毒S蛋白RBD肽段的原核表达与纯化.生物技术通讯.2020,(第03期),42-46. * |
Also Published As
Publication number | Publication date |
---|---|
CN113817051A (zh) | 2021-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111690059B (zh) | 一种抗SARS-CoV-2的单克隆抗体1D7 | |
CN111718411B (zh) | 一种抗SARS-CoV-2的单克隆抗体1F2 | |
US20230064544A1 (en) | Anti-ctla4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses | |
CN112521494B (zh) | 一种抗SARS-CoV-2的单克隆抗体2B11 | |
CN111732654B (zh) | 一种抗SARS-CoV-2的单克隆抗体1E10 | |
CN108779179B (zh) | Cd47抗体、其抗原结合片段及其医药用途 | |
CN110016079B (zh) | 抗呼吸道合胞病毒的中和抗体及其应用 | |
CN105992772A (zh) | IgA多特异性结合分子 | |
CN113354733B (zh) | 一种抗SARS-CoV-2流行突变株的单克隆抗体20D8 | |
US20120269822A1 (en) | Anti-Botulinum Neurotoxin a Single Domain Antibody Antibodies | |
KR20230017226A (ko) | Cd40 결합 단백질 | |
CN113508139A (zh) | 结合人lag-3的抗体、其制备方法和用途 | |
CN113527473A (zh) | 一种全人源单克隆抗体及其应用 | |
CN115093477A (zh) | 一种抗新型冠状病毒核蛋白n端区的单克隆抗体及其应用 | |
CN113817051B (zh) | 一种抗SARS-CoV-2的单克隆抗体1B6 | |
WO2019128119A1 (zh) | 一种针对破伤风毒素的全人源单克隆中和抗体及其应用 | |
JP2014526886A (ja) | マクロファージ遊走阻止因子(mif)とd−ドーパクロームトートメラーゼ(d−dt)に交差反応性がある抗体 | |
CN113817050B (zh) | 一种抗SARS-CoV-2的单克隆抗体1H8 | |
CN108610417B (zh) | 抗破伤风毒素中和抗体、其制备方法及用途 | |
CN115260306A (zh) | 靶向SARS-CoV-2受体结合基序的单克隆抗体及其识别抗原表位和应用 | |
WO2022095996A1 (zh) | 抗SARS-CoV-2抗体及其应用 | |
CN117402237A (zh) | 一种抗新型冠状病毒的双特异性抗体及其应用 | |
CN115337396A (zh) | 一种全人源单克隆抗体组合及其应用 | |
CN116496390A (zh) | 一种抗新型冠状病毒核蛋白c端区的单克隆抗体及其应用 | |
CN116891531A (zh) | 一种抗新冠病毒变异株的全人源双特异性抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |